Skip to main content

Table 1 RT-PCR analysis for selected genes in chromosomal regions of deletion or amplification/duplication in primary RCC tumours and associated normal tissue

From: Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma

Deletions
Chromosome Potential tumour specifically inactivated genes  
Tum Exp. Lost/Tum. Exp. Down-regulated/Tum. Exp. Normal or Up-regulated (Percentage of lost/down-regulated)  
Chromosome 1 CHD5 TNFRSF1B KIF17 UQCRH GPX7
0/1/14 (6.7%) 0/0/15 (0.0%) 0/0/15 (0.0%) 0/0/15 (0.0%) 0/0/15 (0.0%)
TTC22 PDE4DIP RGS7 TRIM58  
1/1/13 (13.3%) 0/0/15 (0.0%) 3/4/8 (46.7%) 0/2/13 (13.1%)  
Chromosome 6 GCM2 HIST1H3G HIST1H4H   
8/0/2 (80.0%) 0/0/15 (0.0%) 0/0/15 (0.0%)   
Chromosome 8p GATA4 NEFM    
1/0/8 (11.1%) 1/2/12 (20.0%)    
Chromosome 14q EFS PTGDR C14orf39 FLRT2  
0/1/14 (6.7%) 0/1/14 (6.7%) 1/0/8 (11.1%) 0/1/14 (6.7%)  
Amplifications
Chromosome Potential tumour specifically inactivated genes  
  (Percentage of tumours in which gene expression is lost or down-regulated in brackets)  
Chromosome 1 TWIST1 HOXA11 AEBP1 KLF14  
  1/0/13 (7.1%)1 0/2/13 (13.3%) 3/0/12 (20.0%) 0/2/13 (13.3%)  
Chromosome 8p SOX17 CA3 ANGPT1 TMEM74  
  0/2/13 (13.3%) 0/3/12 (20.0%) 0/0/15 (0.0%) 4/3/8 (46.7%)  
  1. 1Key= Tumour Expression Lost/Tumour Expression Down-regulated/Tumour Expression Normal or Up-regulated (Percentage of lost/down-regulated).
  2. Genes in bold type (GCM2, RGS7 and NEFM) demonstrated complete loss or downregulation of expression in at least 20% of RCC tumours and were located in regions of deletion.